MedTrace Logo

Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer

NCT02115152 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-04-15

No results posted yet for this study

Summary

This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).

Conditions

  • Stage II Breast Cancer
  • Stage III Breast Cancer

Interventions

DRUG

fluorouracil

DRUG

capecitabine

DRUG

cyclophosphamide

DRUG

Epirubicin

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Jianlun Liu, MD · Guangxi Medical University Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02115152 on ClinicalTrials.gov